326030.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:30):

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders...

Stats
Dzisiejszy wolumen	0.00
Średni wolumen	129 391
Kapitalizacja rynkowa	6 781.93B
EPS	KRW0 ( 2024-03-17 )
Następna data zysków	( KRW46.28 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW131.70 (0.15%)

Wolumen Korelacja

Długi: -0.27 (neutral)

Krótki: -0.92 (very strong negative)

Signal:(38.258) Neutral

SK Biopharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SK Biopharmaceuticals Korelacja - Waluta/Towar

-0.54
( weak negative )

-0.44
( neutral )

-0.66
( moderate negative )

-0.57
( weak negative )

0.51
( weak )

0.44
( neutral )

SK Biopharmaceuticals Finanse

Annual	2023
Przychody:	KRW354.89B
Zysk brutto:	KRW308.37B (86.89 %)
EPS:	KRW-419.89

FY	2023
Przychody:	KRW354.89B
Zysk brutto:	KRW308.37B (86.89 %)
EPS:	KRW-419.89

FY	2022
Przychody:	KRW246.18B
Zysk brutto:	KRW208.41B (84.66 %)
EPS:	KRW-1 780.43

FY	2021
Przychody:	KRW418.64B
Zysk brutto:	KRW396.31B (94.66 %)
EPS:	KRW903.57

Financial Reports:

No articles found.

SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.